Reuters logo
BRIEF-Exelixis to receive milestone payment from Bristol-Myers Squibb
October 4, 2017 / 12:18 PM / in 19 days

BRIEF-Exelixis to receive milestone payment from Bristol-Myers Squibb

Oct 4 (Reuters) - Exelixis Inc

* Exelixis to receive milestone payment from Bristol-Myers Squibb for submission of clinical trial authorization for RORγt inverse agonist program

* Exelixis Inc says ‍has earned a $10 million milestone payment from Bristol-Myers Squibb under terms of two companies’ worldwide collaboration​

* Exelixis - milestone payment triggered by Bristol-Myers Squibb’s filing of clinical trial authorization in Europe for first-in-human study of RORγt inverse agonist​

* Exelixis - could potentially receive additional development and regulatory milestones of up to $240 million, commercialization milestones of up to $150 million Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below